IDXX stock forecast, quote, news & analysis
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock... Show more
Why IDEXX Laboratories (IDXX) Stock Is Up +35% in the Last 30 Days
Key Takeaways
- IDEXX Laboratories shares climbed roughly 35% over the past 30 days, rising from about $520 to above $700.
- The advance was driven primarily by a stronger-than-expected third-quarter earnings report and a raised full-year outlook announced in early November.
- Third-quarter revenue rose 10% organically to approximately $1.21 billion, while diluted EPS of $4.01 increased 18% on a reported basis and 22% on a comparable basis.
- Companion Animal Group diagnostics recurring revenue grew 11% organically, led by 14% growth in international markets.
- The company raised its full-year 2026 revenue and earnings-per-share guidance for the third time this year.
- Shares rallied even as U.S. same-store clinical visits declined an estimated 1.8% in the quarter, reflecting higher testing intensity per visit.
- For deeper data on this ticker, explore Price Targets, Earnings, and Forecast pages for additional analysis.
- For automated trading insights across the market, explore Trending AI Robots.
IDEXX Laboratories (IDXX) Company Overview and Market Position
IDEXX Laboratories, headquartered in Westbrook, Maine, is a global leader in veterinary diagnostics, with companion animal (pet) diagnostics accounting for roughly 92% of net sales, alongside smaller water-quality and livestock, poultry, and dairy testing businesses. The company sells diagnostic instruments and recurring consumables used in veterinary clinics, operates reference laboratories, and provides practice-management software and services.
Its competitive strength rests on a "razor-and-blade" model: once a clinic installs an IDEXX analyzer such as the inVue Dx or Catalyst platform, it typically orders test consumables for years, creating a large and predictable recurring revenue base. Investors follow the stock closely because this recurring model has historically delivered durable, double-digit growth even during softer periods for clinic traffic.
IDEXX Laboratories (IDXX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, IDXX advanced approximately 35%, from a close near $520 to above $700. The bulk of that gain occurred in a single session in early November, when the stock jumped roughly 22% after third-quarter results.
The picture over the last quarter was more volatile. Shares traded near $567 in early August, then slid into the low $500s by mid-September amid concerns about weakening pet-clinic visit trends. The stock recovered toward the mid-$500s through October before the earnings-driven surge, leaving the shares up roughly 24% over the trailing three-month period.
What Drove IDXX Stock Price in the Last 30 Days
The dominant catalyst was the company's third-quarter earnings report, released in early November. Revenue of approximately $1.21 billion grew 10% both as reported and organically, ahead of consensus near $1.19 billion, while diluted EPS of $4.01 beat analyst estimates and rose 18% year over year. Net income increased 16% to about $317 million.
Growth was led by Companion Animal Group diagnostics recurring revenue, up 11% organically, including 14% international gains. Gross margin expanded to 62.9% and operating margin to 33.1%, each up roughly 100 basis points. IDEXX also raised its full-year 2026 revenue guidance to $4.741 billion to $4.767 billion and EPS guidance to $14.96 to $15.16.
The reaction reflected more than the headline beat. Before the report, shares had been pressured by multi-year declines in U.S. veterinary clinic visits and concerns about pricing. The quarter showed IDEXX can still grow diagnostics revenue through higher testing intensity per visit and new-product adoption even when traffic is soft. The company placed more than 1,900 inVue Dx analyzers, lifting the installed base toward 11,000, and completed its acquisition of CoVet, an AI-native veterinary software provider.
What Drove IDXX Stock Performance Over the Last Quarter
The broader three-month trend was defined by two phases. From August through September, shares declined as investors weighed weak U.S. clinic visit volumes, muted puppy and kitten adoption, and competitive and pricing concerns in companion-animal care. The stock fell from the mid-$560s toward the low $500s.
The narrative shifted sharply in November. Third-quarter results demonstrated the resilience of the recurring revenue model, and the raised full-year outlook prompted investors to re-rate the stock. Analyst responses reflected the repositioning, with at least one firm lifting its price target while maintaining a neutral stance. The move also coincided with broader rotation into healthcare and consumer-related names.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading bots. Tickeron offers hundreds of AI-driven trading robots covering thousands of tickers, but only the top-performing and most relevant bots appear in this section. These bots differ in strategy, timeframe, and performance metrics, allowing traders to filter by criteria that match their approach. The page is designed to help users monitor which automated strategies are currently gaining traction, providing a useful starting point for those exploring algorithmic trading tools.
IDXX Stock Forecast Drivers: What Investors Should Watch Next
Investors will likely focus on whether the company can sustain double-digit organic growth as U.S. clinic visit trends remain soft. Key items include fourth-quarter and full-year results against the raised guidance, continued adoption of inVue Dx and the Cancer Dx panel, and the integration of the CoVet acquisition, which carries near-term EPS dilution. International growth momentum, competitive and pricing dynamics, and the health of consumer spending on pets will also be important. These are factors to monitor, not a basis for any specific investment decision.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
IDXX in +5.36% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IDXX advanced for three days, in 178 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on IDXX as a result. In 53 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.
The Aroon Indicator entered an Uptrend today. In 97 of 171 cases where IDXX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
IDXX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. IDXX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.027) is normal, around the industry mean (67.298). P/E Ratio (47.242) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties